Select Language

IL-10 R alpha

IL-10 R alpha Overview

English Name	Interleukin 10 receptor	Approved Drugs	0
Drugs in Clinical Trials	9	Target Synonym	Receptors， Interleukin-10
Highest Development Stage	Phase 3 Clinical

English Name	Interleukin 10 receptor
Target Synonym	Receptors， Interleukin-10
Approved Drugs	0
Drugs in Clinical Trials	9
Highest Development Stage	Phase 3 Clinical

IL-10 R alpha Product List

Product Category
Protein (4)
Product Status
Launched (4)
Species
Human (2)Cynomolgus (1)Mouse (1)
Tag
Fc Tag & Avi Tag (1)Fc Tag (3)
Conjugate
Biotin-labeled (1)Unconjugated (3)

Cat. No.	Species	Host	Product Description
HOT ILR-H82F6	Human	HEK293	Biotinylated Human IL-10 R alpha / CD210 Protein, Fc,Avitag™ (MALS verified)
HOT ILR-M5254	Mouse	HEK293	Mouse IL-10 R alpha / CD210 Protein, Fc Tag
HOT ILR-C5256	Cynomolgus	HEK293	Cynomolgus IL-10 R alpha / CD210 Protein, Fc Tag
ILR-H525a	Human	HEK293	Human IL-10 R alpha / CD210 Protein, Fc Tag (MALS verified)

Total: 4

IL-10 R alpha Background

Interleukin-10 receptor subunit alpha (IL-10 R alpha ) is a cell surface receptor for the cytokine IL-10 that participates in IL-10 mediated anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Upon binding to IL10, induces a conformational change in IL10RB, allowing IL10RB to bind IL10 as well.In turn, the heterotetrameric assembly complex, composed of two subunits of IL10RA and IL10RB, activates the kinases JAK1 and TYK2 that are constitutively associated with IL10RA and IL10RB respectively.These kinases then phosphorylate specific tyrosine residues in the intracellular domain in IL10RA leading to the recruitment and subsequent phosphorylation of STAT3

IL-10 R alpha Synonyms

Interleukin-10 receptor subunit alpha,IL-10 receptor subunit alpha,IL-10R subunit alpha,IL-10RA,CDw210a,Interleukin-10 receptor subunit 1,IL-10R subunit 1,IL-10R1,CD210,IL10RA,IL10R

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
IAE-0972	IAE-0972	Phase 3 Clinical	SunHo (China) BioPharmaceutical Co Ltd	Carcinoma, Basosquamous; Carcinoma, Hepatocellular; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details
Recombinant anti-human EGFR antibody/IL-10 bispecific Fc fusion protein(Dingfu Biotarget)	CmAb-(IL10)2; DF203; DF-203	Phase 2 Clinical	Dingfu Biotarget Co Ltd	Ascites; Pleural Effusion, Malignant; Solid tumours	Details
AG-019	AG-019	Phase 2 Clinical	Precigen Actobio Inc	Diabetes Mellitus, Type 1	Details
Meta 10C-IL-10 TILs	Meta10-TIL; Meta 10C-IL-10 TILs	Phase 2 Clinical	Leman Biotech Co Ltd	Neoplasms; Solid tumours	Details
IBB-0979	IBB0979; IBB-0979	Phase 2 Clinical	SunHo (China) BioPharmaceutical Co Ltd	Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Neoplasms; Peritoneal Neoplasms; Small Cell Lung Carcinoma; Solid tumours	Details
Vimekofusp	AMT-101 (Applied Molecular Transport)	Phase 2 Clinical	Applied Molecular Transport	Colitis, Ulcerative	Details
F8-IL10	F8-IL10; PF-06687234	Phase 2 Clinical	Philogen Spa	Arthritis, Rheumatoid; Colitis, Ulcerative; Inflammatory Bowel Diseases	Details
PEG-ilodecakin	AM-0010	Phase 1 Clinical	Armo Biosciences, Merck Sharp & Dohme Corp	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Granulomatosis with Polyangiitis; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Vasculitis	Details
Diakine-DK2 10 (EGFR)	DK210; DK-2-10	Phase 1 Clinical	Deka Biosciences Inc	Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Pancreatic Neoplasms; Skin Neoplasms; Solid tumours	Details